The Technical Analyst
Select Language :
Clovis Oncology, Inc. [CLVS]

Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology

Clovis Oncology, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Clovis Oncology, Inc. is listed at the NASDAQ Exchange

0.00% $0.0812

/ 20 des 2022 @ 16:00


Clovis Oncology, Inc.: Main Fundamentals PE comparison

RATING 2023-02-22
B
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Buy
Return On Asset: Sell
DE: Sell
P/E: Sell
Price To Book: Neutral
QUARTER GROWTHS
2/213/214/211/222/223/22
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.0390 | sector: PE 0
PE RATIO: COMPANY / INDUSTRY
0x
Company: PE -0.0390 | industry: PE 0
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 0.0042 - 0.158

( +/- 94.83%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-11-01 Gross Paul Edward Buy 4 625 Common Stock
2022-11-01 Gross Paul Edward Buy 5 623 Common Stock
2022-11-02 Gross Paul Edward Sell 2 135 Common Stock
2022-11-02 Gross Paul Edward Sell 2 595 Common Stock
2022-11-01 Gross Paul Edward Sell 4 625 Restricted Stock Units
INSIDER POWER
-0.21
Last 100 transactions
Buy: 146 624 | Sell: 133 052

Forecast: 01:40 - $0.216

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.0812 (0.00% )
Volume 24.21 mill
Avg. Vol. 5.97 mill
% of Avg. Vol 405.48 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Clovis Oncology, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Clovis Oncology, Inc.

RSI

Intraday RSI14 chart for Clovis Oncology, Inc.

Last 10 Buy & Sell Signals For CLVS

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Clovis Oncology, Inc.

CLVS

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Last 10 Buy Signals

Date Signal @
GALXUSDMar 19 - 04:584.59
BIFIUSDMar 19 - 04:59355.24
CTXUSDMar 19 - 04:594.81
BRG.OLMar 19 - 04:44NOK185.80
ABG.OLMar 19 - 04:30NOK5.81
PAXGUSDMar 19 - 04:562 123.79
LSG.OLMar 19 - 04:42NOK48.00
EPR.OLMar 19 - 04:42NOK74.20
WBTCUSDMar 19 - 04:5662 981
BATUSDMar 19 - 04:56$0.266

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.